[go: up one dir, main page]

WO2018089863A1 - Formulations pour administration efficace de cannabinoïdes - Google Patents

Formulations pour administration efficace de cannabinoïdes Download PDF

Info

Publication number
WO2018089863A1
WO2018089863A1 PCT/US2017/061202 US2017061202W WO2018089863A1 WO 2018089863 A1 WO2018089863 A1 WO 2018089863A1 US 2017061202 W US2017061202 W US 2017061202W WO 2018089863 A1 WO2018089863 A1 WO 2018089863A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
lozenge
cannabinoids
thc
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/061202
Other languages
English (en)
Inventor
Benjamin F. Ross
Jerry B. Gin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bennes Inc
Original Assignee
Bennes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bennes Inc filed Critical Bennes Inc
Priority to CA3046638A priority Critical patent/CA3046638A1/fr
Priority to EP17869632.4A priority patent/EP3538078A4/fr
Publication of WO2018089863A1 publication Critical patent/WO2018089863A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • THC has mild to moderate analgesic effects
  • cannabis can be used to treat pain by altering transmitter release on dorsal root ganglion of the spinal cord and in the periaqueductal gray.
  • Other effects include relaxation, alteration of visual, auditory, and olfactory senses, fatigue, and appetite stimulation.
  • THC has marked anti-emetic properties, and may also reduce aggression in certain subjects.
  • THC helps alleviate symptoms suffered both by AIDS patients, and by cancer patients undergoing chemotherapy, by increasing appetite and decreasing nausea. It has also been shown to assist some glaucoma patients by reducing pressure within the eye, and is used in the form of cannabis by a number of multiple sclerosis patients, who use it to alleviate neuropathic pain and spasticity.
  • Cannabidiol (“CBD”) is one of at least 85 cannabinoids found in cannabis. It is a major constituent of the plant, second to THC, and represents up to 40% in its extracts.
  • ETHOCEL® Standard 14 Premium solution viscosity range approximately 12.6 to 15.4 cP, ethoxyl content 48.0-49.5%
  • ETHOCEL® Standard 20 Premium solution viscosity range approximately 18 to 22 cP, ethoxyl content 48.0-49.5%
  • ETHOCEL® Standard 45 Premium solution viscosity range approximately 41 to 49 cP, ethoxyl content 48.0-49.5%
  • the lozenges are prepared by admixture of the hydrophilic polymer and the flavoring agent and any additional components, including sweeteners, colorants, other additives discussed herein, and additional beneficial agents. Admixture can generally be carried out at room temperature and ambient humidity, unless a particular beneficial agent or other component of the lozenge requires a protected environment, a lower temperature, or lower humidity. Using the appropriate weight ratio of the hydrophilic polymer to the flavoring agent as discussed supra, admixture of the components results in a pliable wet matrix that can be formed into a roll or sheet. After allowing the composition to set, typically over a 24-hour period, the lozenges are then created by cutting of the roll or die cutting of the sheet.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des pastilles comprenant de la cellulose d'éthyle et des cannabinoïdes pour une administration rapide et efficace de cannabinoïdes médicaux. La pastille est appropriée pour l'administration du(des) cannabinoïde(s) à travers la muqueuse buccale dans la circulation sanguine. Des modes de réalisation de la pastille sont décrits qui comprennent des additifs qui atténuent d'autres problèmes liés à l'administration de cannabinoïdes. Les additifs décrits comprennent de la gomme xanthane pour atténuer le syndrome de la bouche sèche, des huiles essentielles pour des activités aromatisantes et antibactériennes, du zinc pour l'amélioration de l'haleine, des exhausteurs de perméation et des bicarbonates de métaux alcalins pour réduire l'acidité dans la bouche. L'invention concerne également des méthodes de fabrication des pastilles et leur utilisation dans le traitement d'états pathologiques.
PCT/US2017/061202 2016-11-11 2017-11-11 Formulations pour administration efficace de cannabinoïdes Ceased WO2018089863A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3046638A CA3046638A1 (fr) 2016-11-11 2017-11-11 Formulations pour administration efficace de cannabinoides
EP17869632.4A EP3538078A4 (fr) 2016-11-11 2017-11-11 Formulations pour administration efficace de cannabinoïdes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662420981P 2016-11-11 2016-11-11
US62/420,981 2016-11-11

Publications (1)

Publication Number Publication Date
WO2018089863A1 true WO2018089863A1 (fr) 2018-05-17

Family

ID=62110287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/061202 Ceased WO2018089863A1 (fr) 2016-11-11 2017-11-11 Formulations pour administration efficace de cannabinoïdes

Country Status (3)

Country Link
EP (1) EP3538078A4 (fr)
CA (1) CA3046638A1 (fr)
WO (1) WO2018089863A1 (fr)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108703963A (zh) * 2018-07-02 2018-10-26 宁夏医科大学 茴香脑在制备治疗神经病理性疼痛药物中的用途
WO2019051560A1 (fr) * 2017-09-15 2019-03-21 Zelda Therapeutics Operations Pty Ltd Composition et méthode de traitement de l'autisme
CN109758450A (zh) * 2019-03-06 2019-05-17 天津医科大学 一种抗肿瘤新化合物、及其制备方法和用途
US20200061023A1 (en) * 2018-08-27 2020-02-27 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
WO2020046947A1 (fr) * 2018-08-27 2020-03-05 Axcess Global Sciences, Llc Compositions et méthodes pour administrer du cannabidiol et des corps cétoniques
US10588876B2 (en) 2017-11-22 2020-03-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596128B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
WO2020210058A1 (fr) * 2019-04-10 2020-10-15 G.I Pharmaceuticals, Inc. Nouveau procédé pour le traitement de la dyspepsie, des intolérances alimentaires et médicales, du syndrome du côlon irritable et autres troubles gastro-intestinaux fonctionnels
WO2020211912A1 (fr) * 2019-04-17 2020-10-22 Nordiccan A/S Pastille à administration améliorée de cannabinoïdes
WO2020211911A1 (fr) * 2019-04-17 2020-10-22 Nordiccan A/S Formulation de pastille de cannabinoïde
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
CN112839645A (zh) * 2018-08-07 2021-05-25 艾利特有限责任公司 用于治疗性功能障碍和增强性反应和快感的组合物和方法
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US11084770B2 (en) 2016-12-07 2021-08-10 Treehouse Biotech, Inc. Cannabis extracts
US20210251950A1 (en) * 2019-07-08 2021-08-19 Aaron Miles System and Method for Incorporating CBD/THC Cannabinoid Nanoparticle Carrier Compositions into Particulate Foods and Food Additives
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
WO2021195540A1 (fr) * 2020-03-26 2021-09-30 Radient Technologies Innovations Inc. Composition à base de cannabinoïdes pour l'atténuation d'effets viraux
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
WO2022189432A1 (fr) * 2021-03-09 2022-09-15 Nutrition & Biosciences Usa 1, Llc Composition d'oléogel comprenant une éthylcellulose et un ingrédient actif huileux
CN115151241A (zh) * 2019-08-09 2022-10-04 朱庇特健康公司 Cbd制剂及其用途
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
US20230165850A1 (en) * 2020-05-07 2023-06-01 Liw Innovation Ab New compositions for oral or nasal use
WO2023114529A3 (fr) * 2021-12-17 2023-10-26 Bennes, Inc. Formulations pharmacoactives pour administration de composés psychédéliques
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12128020B2 (en) 2016-04-19 2024-10-29 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
GB2632418A (en) * 2023-08-04 2025-02-12 Anthony Neish Jason Oral compositions
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12433912B2 (en) 2019-05-15 2025-10-07 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US12496283B2 (en) 2024-10-09 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3820530A4 (fr) * 2018-07-10 2022-03-30 Cardinal Advisory Limited Formulation de composés cannabinoïdes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081294A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
US20140329895A1 (en) * 2008-02-08 2014-11-06 Nektar Therapeutics Oligomer-cannabinoid conjugates
US20160074451A1 (en) * 2014-04-17 2016-03-17 Gary J. Speier Pharmaceutical composition and method of manufacturing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539069A4 (fr) * 2002-05-31 2007-11-14 Univ Mississippi Administration par voie transmuqueuse de cannabinoides
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
EP3160451B1 (fr) * 2014-06-27 2021-04-07 Farm To Farma, Inc. Formulations de cannabinoïde buccale et sublinguale, et leur procédé de fabrication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081294A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
US20140329895A1 (en) * 2008-02-08 2014-11-06 Nektar Therapeutics Oligomer-cannabinoid conjugates
US20160074451A1 (en) * 2014-04-17 2016-03-17 Gary J. Speier Pharmaceutical composition and method of manufacturing

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Lozenges and Medication Sticks", THE PHARMACEUTICS AND COMPOUNDING LABORATORY , 24 September 2015 (2015-09-24), pages 1, XP009515027, Retrieved from the Internet <URL:https://web.archive.org/web/20150924183539/https://pharmlabs.unc.edu/labs/lozenge/lozenges.htm> [retrieved on 20180205] *
See also references of EP3538078A4 *

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896565B2 (en) 2016-03-11 2024-02-13 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US11020362B2 (en) 2016-03-11 2021-06-01 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US12350243B2 (en) 2016-04-19 2025-07-08 Axcess Global Sciences, Llc Compositions and compounds containing beta-hydroxybutyrate and one or more amino acids
US12251362B2 (en) 2016-04-19 2025-03-18 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12128020B2 (en) 2016-04-19 2024-10-29 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11084770B2 (en) 2016-12-07 2021-08-10 Treehouse Biotech, Inc. Cannabis extracts
WO2019051560A1 (fr) * 2017-09-15 2019-03-21 Zelda Therapeutics Operations Pty Ltd Composition et méthode de traitement de l'autisme
AU2018101357B4 (en) * 2017-09-15 2022-03-17 Zelira Therapeutics Operations Pty Ltd Composition and method for treating autism
US11786499B2 (en) 2017-11-22 2023-10-17 Axcess Global Sciences, Llc Ketone body esters of S-beta-hydroxybutyrate and/or S-1,3-butanediol for modifying metabolic function
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11690817B2 (en) 2017-11-22 2023-07-04 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10588876B2 (en) 2017-11-22 2020-03-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US10596128B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11793778B2 (en) 2018-04-18 2023-10-24 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
CN108703963A (zh) * 2018-07-02 2018-10-26 宁夏医科大学 茴香脑在制备治疗神经病理性疼痛药物中的用途
CN112839645A (zh) * 2018-08-07 2021-05-25 艾利特有限责任公司 用于治疗性功能障碍和增强性反应和快感的组合物和方法
US20200061023A1 (en) * 2018-08-27 2020-02-27 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
WO2020046947A1 (fr) * 2018-08-27 2020-03-05 Axcess Global Sciences, Llc Compositions et méthodes pour administrer du cannabidiol et des corps cétoniques
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
CN109758450A (zh) * 2019-03-06 2019-05-17 天津医科大学 一种抗肿瘤新化合物、及其制备方法和用途
WO2020210058A1 (fr) * 2019-04-10 2020-10-15 G.I Pharmaceuticals, Inc. Nouveau procédé pour le traitement de la dyspepsie, des intolérances alimentaires et médicales, du syndrome du côlon irritable et autres troubles gastro-intestinaux fonctionnels
US11241413B2 (en) 2019-04-17 2022-02-08 Nordiccan A/S Cannabinoid lozenge formulation
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
WO2020211912A1 (fr) * 2019-04-17 2020-10-22 Nordiccan A/S Pastille à administration améliorée de cannabinoïdes
WO2020211911A1 (fr) * 2019-04-17 2020-10-22 Nordiccan A/S Formulation de pastille de cannabinoïde
US11903919B2 (en) 2019-04-17 2024-02-20 Nordiccan A/S Oral cannabinoid tablet
CN113727704A (zh) * 2019-04-17 2021-11-30 诺狄更斯公司 大麻素锭剂制剂
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US12433912B2 (en) 2019-05-15 2025-10-07 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US20210251950A1 (en) * 2019-07-08 2021-08-19 Aaron Miles System and Method for Incorporating CBD/THC Cannabinoid Nanoparticle Carrier Compositions into Particulate Foods and Food Additives
US12274690B2 (en) * 2019-07-08 2025-04-15 Aaron Miles System and method for incorporating CBD/THC cannabinoid nanoparticle carrier compositions into particulate foods and food additives
CN115151241A (zh) * 2019-08-09 2022-10-04 朱庇特健康公司 Cbd制剂及其用途
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
WO2021195540A1 (fr) * 2020-03-26 2021-09-30 Radient Technologies Innovations Inc. Composition à base de cannabinoïdes pour l'atténuation d'effets viraux
US20230165850A1 (en) * 2020-05-07 2023-06-01 Liw Innovation Ab New compositions for oral or nasal use
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
US20240156731A1 (en) * 2021-03-09 2024-05-16 Nutrition & Biosciences Usa 1, Llc An oleogel composition comprising an ethylcellulose and an oily active ingredient
WO2022189432A1 (fr) * 2021-03-09 2022-09-15 Nutrition & Biosciences Usa 1, Llc Composition d'oléogel comprenant une éthylcellulose et un ingrédient actif huileux
WO2023114529A3 (fr) * 2021-12-17 2023-10-26 Bennes, Inc. Formulations pharmacoactives pour administration de composés psychédéliques
US12144814B2 (en) 2023-03-10 2024-11-19 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
GB2632418A (en) * 2023-08-04 2025-02-12 Anthony Neish Jason Oral compositions
US12496283B2 (en) 2024-10-09 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans

Also Published As

Publication number Publication date
EP3538078A1 (fr) 2019-09-18
EP3538078A4 (fr) 2020-07-08
CA3046638A1 (fr) 2018-05-17

Similar Documents

Publication Publication Date Title
WO2018089863A1 (fr) Formulations pour administration efficace de cannabinoïdes
US11844763B2 (en) Pharmaceutical composition and method of manufacturing
US11938160B2 (en) Pharmaceutical composition and method of manufacturing
US20160058866A1 (en) Alternative solutions for the administration of cannabis derived botanical products
US11730715B2 (en) Consumable compositions and methods of producing the same
US20220257689A1 (en) Chewing gum compositions for the treatment of menstrual pain
US20250360176A1 (en) Chewing gum containing synergistic medicinal compounds
CN102742714A (zh) 一种祛烟瘾清心醒脑的口香糖
CA2893277C (fr) Composition comprenant du raphanus, du theobroma et de la passiflora pour le traitement de l&#39;abus d&#39;opioides et d&#39;alcool
US20220062360A1 (en) Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
US9597278B2 (en) Compositions and methods for alleviating hyposalivation and for providing oral comfort
JP2005089374A (ja) 血糖値上昇抑制機能性飲食品
WO2021188612A1 (fr) Compositions médicamenteuses à base de cannabinoïdes, procédés de fabrication et méthodes de traitement

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17869632

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 3046638

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017869632

Country of ref document: EP

Effective date: 20190611